<div id="readability-page-1"><div><p>As Asian markets experience a period of growth, bolstered by strong corporate earnings and resilient economic indicators, investors are increasingly focusing on companies with robust insider ownership. In this environment, stocks that combine high insider stakes with significant expected earnings growth can present compelling opportunities for those seeking to align their interests with company insiders who have a vested interest in the firm's success.</p><h3>Top 10 Growth Companies With High Insider Ownership In Asia</h3><table><tbody><tr><td><strong>Name</strong></td><td><strong>Insider Ownership</strong></td><td><strong>Earnings Growth</strong></td></tr><tr><td>Vuno (KOSDAQ:A338220)</td><td>15.6%</td><td>109.8%</td></tr><tr><td>Techwing (KOSDAQ:A089030)</td><td>19.1%</td><td>68%</td></tr><tr><td>Suzhou Sunmun Technology (SZSE:300522)</td><td>35.4%</td><td>77.7%</td></tr><tr><td>Sineng ElectricLtd (SZSE:300827)</td><td>36%</td><td>25.8%</td></tr><tr><td>Shanghai Huace Navigation Technology (SZSE:300627)</td><td>24.3%</td><td>24.3%</td></tr><tr><td>Novoray (SHSE:688300)</td><td>23.6%</td><td>28.2%</td></tr><tr><td>M31 Technology (TPEX:6643)</td><td>30.8%</td><td>95.5%</td></tr><tr><td>Laopu Gold (SEHK:6181)</td><td>35.5%</td><td>43%</td></tr><tr><td>Gold Circuit Electronics (TWSE:2368)</td><td>31.4%</td><td>32.8%</td></tr><tr><td>Fulin Precision (SZSE:300432)</td><td>12.8%</td><td>43.7%</td></tr></tbody></table><p>Click here to see the full list of 593 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.</p><p>Let's explore several standout options from the results in the screener.</p><h2>RemeGen (SEHK:9995)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p><p><strong>Overview:</strong> RemeGen Co., Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing biologics for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States with a market cap of approximately HK$40.14 billion.</p><p><strong>Operations:</strong> RemeGen's revenue from biopharmaceutical research, service, production, and sales amounts to approximately CN¥1.91 billion.</p><p><strong>Insider Ownership:</strong> 11.2%</p><p><strong>Earnings Growth Forecast:</strong> 66.3% p.a.</p><p>RemeGen is experiencing significant growth, with earnings forecasted to grow 66.34% annually and revenue expected to increase by 24.6% per year, outpacing the Hong Kong market. Despite high share price volatility, it trades at a notable discount below its estimated fair value. Recent developments include FDA clearance for clinical trials of RC148 in the US and a global Phase 3 trial for Telitacicept, highlighting its innovative drug pipeline and potential for future expansion in international markets.</p><ul><li>Unlock comprehensive insights into our analysis of RemeGen stock in this growth report.</li><li>Our comprehensive valuation report raises the possibility that RemeGen is priced higher than what may be justified by its financials.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/earnings-and-revenue-growth"/><figcaption>SEHK:9995 Earnings and Revenue Growth as at Aug 2025</figcaption></figure><h2>Anhui Estone Materials TechnologyLtd (SHSE:688733)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p><p><strong>Overview:</strong> Anhui Estone Materials Technology Co., Ltd specializes in lithium battery coating, electronic communication functional filling, and low-smoke halogen-free flame-retardant materials in China with a market cap of CN¥5.24 billion.</p><p><strong>Operations:</strong> The company generates revenue of CN¥510.72 million from its specialty chemicals segment.</p><p><strong>Insider Ownership:</strong> 32.8%</p><p><strong>Earnings Growth Forecast:</strong> 60.8% p.a.</p><p>Anhui Estone Materials Technology Ltd. is projected to see robust expansion, with earnings anticipated to grow 60.8% annually and revenue expected to rise by 23.7% per year, surpassing the Chinese market's growth rates. The company recently turned profitable but faces challenges from large one-off items affecting its financial results. Despite these hurdles, no substantial insider trading activity has been reported in recent months, indicating stability in insider sentiment toward the company's prospects.</p><ul><li>Click here to discover the nuances of Anhui Estone Materials TechnologyLtd with our detailed analytical future growth report.</li><li>Our valuation report unveils the possibility Anhui Estone Materials TechnologyLtd's shares may be trading at a premium.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/87d4bd03-6a8a-4073-9576-545895fcbe5f/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/87d4bd03-6a8a-4073-9576-545895fcbe5f/chart/ownership-breakdown"/><figcaption>SHSE:688733 Ownership Breakdown as at Aug 2025</figcaption></figure><h2>Caliway Biopharmaceuticals (TWSE:6919)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p><p><strong>Overview:</strong> Caliway Biopharmaceuticals Co., Ltd. and its subsidiaries focus on developing drugs for aesthetic medicine and chronic inflammation, with a market cap of NT$208.61 billion.</p><p><strong>Operations:</strong> Caliway Biopharmaceuticals Co., Ltd. generates revenue through its focus on drug development for aesthetic medicine and chronic inflammation.</p><p><strong>Insider Ownership:</strong> 24.2%</p><p><strong>Earnings Growth Forecast:</strong> 93.8% p.a.</p><p>Caliway Biopharmaceuticals is experiencing significant growth potential, with revenue forecasted to grow at 89% annually, outpacing the Taiwanese market. The company recently gained recognition by being added to the MSCI Global Standard Index and has initiated pivotal Phase 3 trials for its innovative drug CBL-514. Despite a volatile share price and current lack of meaningful revenue, Caliway's strategic advancements in clinical development position it well for future profitability within three years.</p><ul><li>Delve into the full analysis future growth report here for a deeper understanding of Caliway Biopharmaceuticals.</li><li>The valuation report we've compiled suggests that Caliway Biopharmaceuticals' current price could be inflated.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f979039c-4fc0-497e-ae4c-0aa7995faeba/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f979039c-4fc0-497e-ae4c-0aa7995faeba/chart/earnings-and-revenue-growth"/><figcaption>TWSE:6919 Earnings and Revenue Growth as at Aug 2025</figcaption></figure><h2>Key Takeaways</h2><ul><li>Get an in-depth perspective on all 593 Fast Growing Asian Companies With High Insider Ownership by using our screener here.</li><li>Curious About Other Options? Trump has pledged to &#34;unleash&#34; American oil and gas and these 22 US stocks have developments that are poised to benefit.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation. We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders.      It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities.      All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p></div></div>

688733

688331

09995

<p>As Asian markets grow, investors are focusing on companies with high insider ownership and significant earnings growth. Notable companies include Vuno (15.6% insider ownership, 109.8% earnings growth), Techwing (19.1%, 68%), and RemeGen (11.2%, 66.3%). RemeGen, a biopharmaceutical firm, is expanding with FDA trials and a strong revenue forecast. Anhui Estone Materials Technology (32.8%, 60.8%) and Caliway Biopharmaceuticals (24.2%, 93.8%) also show promising growth potential. The analysis highlights opportunities in Asian growth stocks with insider stakes, emphasizing the alignment of interests between investors and company insiders.</p>

Asian Growth Stocks With Insider Ownership Expecting Up To 93% Earnings Growth